NCT07203521View on ClinicalTrials.gov

RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

194

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

October 7, 2026

Conditions
Acute Large Hemispheric Infarction StrokeTranscranial Bone Marrow InjectionRK-4Acute Ischemic Stroke
Interventions
DRUG

RK-4 injection

take drug RK-4 (2mg/mL, 1mL) by transcranial bone marrow injection once daily for consecutive 3 days.

OTHER

conventional treatment

conventional treatment of LHI other than RK-4

All Listed Sponsors
lead

Fuzhou Neurodawn Rongkang Pharmaceutical Co., Ltd

OTHER_GOV